Could donor stem cells repair hearts damaged by chemo?

NCT ID NCT02962661

First seen Jun 24, 2026 · Last updated Aug 04, 2026 · Updated 5 times

Summary

This early-stage trial is testing whether stem cells from a donor can help control heart failure in people whose hearts were weakened by a type of chemotherapy called anthracyclines. About 72 participants will either receive standard care alone or standard care plus stem cells given through a vein or directly into the heart. The main goal is to check for side effects and see if the stem cells improve heart function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
donor bone marrow derived mesenchymal stem cells
What this could lead to
If it works, this could point toward a new treatment for heart failure caused by chemotherapy, potentially improving heart function and quality of life.
What could go wrong
This is a very early phase 1 trial with only 72 participants, so it is not yet proven to work. There may be side effects from the stem cell infusions or injections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTHRACYCLINE-ASSOCIATED CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.